COVID-19

The acquisition nets Merck a pipeline of oncology programs as well as CD24Fc, OncoImmune's lead candidate for the treatment of COVID-19

Moderna reports interim efficacy results of 94.5 percent for its COVID-19 vaccine candidate

A look at our new online venue for infectious diseases as well as upcoming coverage

ASCB|EMBO annual meeting goes virtual this year with cellular research. Two of the most significant changes aside from the online format are that the meeting will feature seven scientific tracks plus an education and professional development track, in addition to member-organized Special Interest Subgroups being held on three days of the meeting. 

First step is to assess potential therapeutics for COVID-19

Druggable pocket in SARS-CoV-2 spike protein could stop virus

BNT162b2 immunization of rhesus macaques results in strong antiviral effects against SARS-CoV-2

The FDA has authorized the first COVID-19 test for self-testing at home

Precision NanoSystems is developing an mRNA vaccine candidate lipid nanoparticle with CanSinoBIO

Medicago reports positive Phase 1 data for plant-derived COVID-19 vaccine, advances into Phase 2/3 trials